{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:08:36Z","timestamp":1788394116244,"version":"build-2803163510"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray.\n            <jats:bold>Methods:<\/jats:bold>\n            This retrospective cohort study used data collected from a psychiatric clinic's EHR system.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 171 TRD patients received esketamine July 2019\u2013June 2021. This predominantly female, white population had several mental health comorbidities and high exposure to psychiatric medications. We observed significant reductions (p\u00a0&lt;\u00a00.001) in average PHQ-9 and GAD-7 scores from baseline (PHQ-9: mean: 16.7; SD: 5.8; GAD-7: mean: 12.0; SD: 5.8) to last available treatment (PHQ-9: mean: 12.0; SD: 6.4; GAD-7: mean: 8.7; SD: 5.6). There were no reports of serious adverse events.\n            <jats:bold>Conclusion:<\/jats:bold>\n            This study found a significant disease burden for patients with TRD. Esketamine appears to be well tolerated and effective in improving depression and anxiety.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0149","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:57:59Z","timestamp":1667559479000},"page":"1323-1336","source":"Crossref","is-referenced-by-count":42,"title":["Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-3706","authenticated-orcid":false,"given":"Madeline","family":"Brendle","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy, University of Utah College of Pharmacy, UT 84112, USA"},{"name":"Numinus Wellness, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Numinus Wellness, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisa Della","family":"Valle","sequence":"additional","affiliation":[{"name":"Numinus Wellness, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Moore","sequence":"additional","affiliation":[{"name":"Numinus Wellness, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thielking","sequence":"additional","affiliation":[{"name":"Numinus Wellness, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, University of Utah College of Pharmacy, UT 84112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Robison","sequence":"additional","affiliation":[{"name":"Numinus Wellness, UT 84020, USA"},{"name":"University of Utah School of Medicine, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_5_2_2","unstructured":"Hough D. Esketamine. Janssen Pharmaceutical Companies of Johnson and Johnson (2019)."},{"key":"e_1_3_5_3_2","unstructured":"Major depression. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression#part_155028"},{"issue":"2","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu DF","year":"2015","unstructured":"Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin. Neurosci. 17(2), 111\u2013126 (2015).","journal-title":"Dialogues Clin. Neurosci."},{"issue":"11","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905\u20131917 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"e_1_3_5_6_2","first-page":"17m1172","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database","volume":"79","author":"Amos TB","year":"2018","unstructured":"Amos TB, Tandon N, Lefebvre P Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J. Clin. Psychiatry 79(2), 17m1172 (2018).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/NDT.S127453","article-title":"Efficacy and safety of olanzapine\/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials","volume":"13","author":"Luan S","year":"2017","unstructured":"Luan S, Wan H, Wang S, Li H, Zhang B. Efficacy and safety of olanzapine\/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsych. Dis. Treat. 13, 609\u2013620 (2017).","journal-title":"Neuropsych. Dis. Treat."},{"issue":"4","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin DS","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75(4), 336\u2013346 (2018).","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"e_1_3_5_9_2","first-page":"258","article-title":"Suicidality in treatment resistant depression: perspective for ketamine use","volume":"31","author":"Jakuszkowiak-Wojten K","year":"2019","unstructured":"Jakuszkowiak-Wojten K, Ga\u0142uszko-W\u0119gielnik M, Wilkowska A Suicidality in treatment resistant depression: perspective for ketamine use. Psychiatr. Danub. 31(Suppl. 3), 258\u2013260 (2019).","journal-title":"Psychiatr. Danub."},{"issue":"1","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression \u2013 first FDA-approved antidepressant in a new class","volume":"381","author":"Kim J","year":"2019","unstructured":"Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression \u2013 first FDA-approved antidepressant in a new class. N. Engl. J. Med. 381(1), 1\u20134 (2019).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-5380-2-14","article-title":"Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS","volume":"2","author":"Cusin C","year":"2012","unstructured":"Cusin C, Dougherty DD. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biol. Mood Anxiety Disord. 2, 14 (2012).","journal-title":"Biol. Mood Anxiety Disord."},{"issue":"2","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/appi.ajp.2019.19050508","article-title":"All suicidal ideation is not created equal: two cases of suicide attempts during maintenance ketamine treatment","volume":"177","author":"Cusin C","year":"2020","unstructured":"Cusin C, Sakurai H, Bentley K All suicidal ideation is not created equal: two cases of suicide attempts during maintenance ketamine treatment. Am. J. Psychiatry 177(2), 173\u2013174 (2020).","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s13311-017-0537-8","article-title":"Vagal nerve stimulation for treatment-resistant depression","volume":"14","author":"Carreno FR","year":"2017","unstructured":"Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics 14(3), 716\u2013727 (2017).","journal-title":"Neurotherapeutics"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fnins.2020.00284","article-title":"Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice","volume":"14","author":"Yap JYY","year":"2020","unstructured":"Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice. Front. Neurosci. 14, 284 (2020).","journal-title":"Front. Neurosci."},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","DOI":"10.7551\/mitpress\/13258.001.0001","volume-title":"Ketamine.","author":"Moghaddam B","year":"2021","unstructured":"Moghaddam B. Ketamine. MIT Press, USA (2021)."},{"issue":"4","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos P","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol. Psych. 23(4), 801\u2013811 (2018).","journal-title":"Mol. Psych."},{"issue":"10","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41386-019-0365-0","article-title":"Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial","volume":"44","author":"Costi S","year":"2019","unstructured":"Costi S, Soleimani L, Glasgow A Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology 44(10), 1812\u20131819 (2019).","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"e_1_3_5_18_2","first-page":"16","article-title":"The effectiveness and value of esketamine for the management of treatment-resistant depression","volume":"26","author":"Agboola F","year":"2020","unstructured":"Agboola F, Atlas SJ, Touchette DR, Fazioli K, Pearson SD. The effectiveness and value of esketamine for the management of treatment-resistant depression. J. Manag. Care Spec. Pharm. 26(1), 16\u201320 (2020).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"4","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora G","year":"2017","unstructured":"Sanacora G, Frye MA, Mcdonald W A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74(4), 399\u2013405 (2017).","journal-title":"JAMA Psychiatry"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: january 2009\u2013January 2019","volume":"277","author":"Marcantoni WS","year":"2020","unstructured":"Marcantoni WS, Akoumba BS, Wassef M A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: january 2009\u2013January 2019. J. Affect. Disord. 277, 831\u2013841 (2020).","journal-title":"J. Affect. Disord."},{"issue":"7","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.4088\/JCP.17f11738","article-title":"Ketamine for Depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?","volume":"78","author":"Andrade C","year":"2017","unstructured":"Andrade C. Ketamine for Depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J. Clin. Psychiatry 78(7), e852\u2013e857 (2017).","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore J","year":"2019","unstructured":"Dore J, Turnipseed B, Dwyer S Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoactive Drugs 51(2), 189\u2013198 (2019).","journal-title":"J. Psychoactive Drugs"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","DOI":"10.7551\/mitpress\/13258.001.0001","volume-title":"Ketamine.","author":"Moghadam B","year":"2021","unstructured":"Moghadam B. Ketamine. MIT Press, USA (2021)."},{"key":"e_1_3_5_24_2","unstructured":"FDA. Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting; agenda topic: the committees will discuss the efficacy safety and risk-benefit profile of new drug application (NDA) 211243 esketamine 28mg single-use nasal spray device submitted by Janssen Pharmaceuticals Inc. for the treatment of treatment-resistant depression (2019). www.fda.gov\/media\/121376\/download"},{"issue":"12","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner EH","year":"2019","unstructured":"Turner EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6(12), 977\u2013979 (2019).","journal-title":"Lancet Psychiatry"},{"key":"e_1_3_5_26_2","unstructured":"WHO. Fact file on ketamine (2016). https:\/\/sa1s3.patientpop.com\/assets\/docs\/55947.pdf"},{"key":"e_1_3_5_27_2","unstructured":"Janssen. SPRAVATO \u00ae REMS Program Overview (Risk Evaluation and Mitigation Strategy) (2019)."},{"issue":"9","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 16(9), 606\u2013613 (2001).","journal-title":"J. Gen. Intern. Med."},{"issue":"10","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 166(10), 1092\u20131097 (2006).","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","volume":"143","author":"Turkoz I","year":"2021","unstructured":"Turkoz I, Alphs L, Singh J Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Acta Psychiatr. Scand. 143(3), 253\u2013263 (2021).","journal-title":"Acta Psychiatr. Scand."},{"issue":"11","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jama.2019.10728","article-title":"Psychiatric practice patterns and barriers to the adoption of esketamine","volume":"322","author":"Wilkinson ST","year":"2019","unstructured":"Wilkinson ST, Howard DH, Busch SH. Psychiatric practice patterns and barriers to the adoption of esketamine. JAMA 322(11), 1039\u20131040 (2019).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jad.2010.04.030","article-title":"Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods","volume":"127","author":"Mcmillan D","year":"2010","unstructured":"Mcmillan D, Gilbody S, Richards D. Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods. J. Affect. Disord. 127(1), 122\u2013129 (2010).","journal-title":"J. Affect. Disord."},{"key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1017\/S2045796020000268","article-title":"Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui","volume":"29","author":"Mathews M","year":"2020","unstructured":"Mathews M, Daly EJ, Popova V, Heerlein K, Canuso C, Drevets WC. Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui. Epidemiol. Psychiatr. Sci. 29, e124 (2020).","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"e_1_3_5_34_2","unstructured":"Janssen. Spravato (esketamine) nasal spray prescribing information (2019)."},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0276"},{"issue":"5","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/da.23138","article-title":"At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: learnings from a population based study","volume":"38","author":"Cepeda MS","year":"2021","unstructured":"Cepeda MS, Kern DM, Canuso CM. At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: learnings from a population based study. Depress. Anxiety 38(5), 521\u2013527 (2021).","journal-title":"Depress. Anxiety"},{"key":"e_1_3_5_37_2","article-title":"Medicaid enrollees are sicker and more disabled than the privately-insured","author":"Foundation KF","year":"2013","unstructured":"Foundation KF. Medicaid enrollees are sicker and more disabled than the privately-insured. Kaiser Family Foundation (2013).","journal-title":"Kaiser Family Foundation"},{"key":"e_1_3_5_38_2","article-title":"Medicaid cuts would affect older, sicker Americans","author":"Ryan J","year":"2017","unstructured":"Ryan J, Abrams MK. Medicaid cuts would affect older, sicker Americans. The Commonwealth Fund (2017).","journal-title":"The Commonwealth Fund"},{"key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi KS","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adher. 6, 369\u2013388 (2012).","journal-title":"Patient Prefer. Adher."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2022-0149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T14:59:53Z","timestamp":1676645993000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":38,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2217\/cer-2022-0149"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0149","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}